Page 120 - 《中国药房》2024年17期

tor Ⅺ inhibitors：cardiovascular perspectives[J]. Eur Heart comes after acute myocardial infarction[J]. Circulation，
J，2023，44（4）：280-292. 2022，146（16）：1196-1206.
[ 7 ] SZÉKELY O，BORGI M，LIP G Y H. Factor Ⅺ inhibition [18] SHOAMANESH A，MUNDL H，SMITH E E，et al. Fac‐
fulfilling the optimal expectations for ideal anticoagulation tor Ⅺa inhibition with asundexian after acute non-cardio-
[J]. Expert Opin Emerg Drugs，2019，24（1）：55-61. embolic ischaemic stroke（PACIFIC-STROKE）：an inter‐
[ 8 ] BÜLLER H R，BETHUNE C，BHANOT S，et al. Factor national，randomised，double-blind，placebo-controlled，
Ⅺ antisense oligonucleotide for prevention of venous phase 2b trial[J]. Lancet，2022，400（10357）：997-1007.
thrombosis[J]. N Engl J Med，2015，372（3）：232-240. [19] PICCINI J P，CASO V，CONNOLLY S J，et al. Safety of
[ 9 ] WALSH M，BETHUNE C，SMYTH A，et al. Phase 2 the oral factor Ⅺa inhibitor asundexian compared with
study of the factor Ⅺ antisense inhibitor IONIS-FⅪRx in apixaban in patients with atrial fibrillation （PACIFIC-
patients with ESRD[J]. Kidney Int Rep，2021，7（2）： AF）：a multicentre，randomised，double-blind，double-
200-209. dummy，dose-finding phase 2 study[J]. Lancet，2022，399
[10] ZHANG H，LÖWENBERG E C，CROSBY J R，et al. Inhi‐ （10333）：1383-1390.
bition of the intrinsic coagulation pathway factor Ⅺ by an‐ [20] BEALE D，DENNISON J，BOYCE M，et al. ONO-7684，
tisense oligonucleotides：a novel antithrombotic strategy a novel oral FⅪa inhibitor：safety，tolerability，pharmaco‐
with lowered bleeding risk[J]. Blood，2010，116（22）： kinetics and pharmacodynamics in a first-in-human study
4684-4692. [J]. Br J Clin Pharmacol，2021，87（8）：3177-3189.
[11] Ionis Pharmaceuticals Inc. Ionis announces positive [21] MA T T，DONG Y L，HUANG L，et al. SHR2285，the
topline results from phase 2b clinical study of fesomersen， first selectively oral FⅪa inhibitor in China：safety，tole-
a potential novel anti-thrombotic treatment[EB/OL]. rability，pharmacokinetics and pharmacodynamics com‐
（2022-07-28）[2024-08-10]. https：//www.prnewswire.com/ bined with aspirin，clopidogrel or ticagrelor[J]. Front Phar‐
news-releases/ionis-announces-positive-topline-results- macol，2022，13：1027627.
from-phase-2b-clinical-study-of-fesomersen-a-potential- [22] POLLACK C V Jr，KURZ M A，HAYWARD N J. EP-
novel-anti-thrombotic-treatment-301594902.html. 7041，a factor Ⅺa inhibitor as a potential antithrombotic
[12] YI B A，FREEDHOLM D，WIDENER N，et al. Pharmaco‐ strategy in extracorporeal membrane oxygenation：a brief
kinetics and pharmacodynamics of Abelacimab （MAA868）， report[J]. Crit Care Explor，2020，2（9）：e0196.
a novel dual inhibitor of factor Ⅺ and factor Ⅺ a[J]. J [23] PERERA V，LUETTGEN J M，WANG Z Q，et al. First-in-
Thromb Haemost，2022，20（2）：307-315. human study to assess the safety，pharmacokinetics and
[13] KOULAS I，SPYROPOULOS A C. A review of FⅪa inhi‐ pharmacodynamics of BMS-962212，a direct，reversible，
bition as a novel target for anticoagulation[J]. Hamostaseo- small molecule factor Ⅺa inhibitor in non-Japanese and
logie，2023，43（1）：28-36. Japanese healthy subjects[J]. Br J Clin Pharmacol，2018，
[14] WEITZ J I，BAUERSACHS R，BECKER B，et al. Effect 84（5）：876-887.
of osocimab in preventing venous thromboembolism [24] CHEN W，CARVALHO L P，CHAN M Y，et al. Fasxia‐
among patients undergoing knee arthroplasty： the tor，a novel factor Ⅺa inhibitor from snake venom，and its
FOXTROT randomized clinical trial[J]. JAMA，2020，323 site-specific mutagenesis to improve potency and selecti-
（2）：130-139. vity[J]. J Thromb Haemost，2015，13（2）：248-261.
[15] LORENTZ C U，VERBOUT N G，WALLISCH M，et al. [25] PIREAUX V，TASSIGNON J，DEMOULIN S，et al. Anti‐
Contact activation inhibitor and factor Ⅺ antibody， coagulation with an inhibitor of factors Ⅺa and Ⅻa du-
AB023，produces safe，dose-dependent anticoagulation in ring cardiopulmonary bypass[J]. J Am Coll Cardiol，2019，
a phase 1 first-in-human trial[J]. Arterioscler Thromb Vasc 74（17）：2178-2189.
Biol，2019，39（4）：799-809. [26] DONKOR D A，BHAKTA V，ELTRINGHAM-SMITH L
[16] PERERA V，WANG Z Q，LUETTGEN J，et al. First-in- J，et al. Selection and characterization of a DNA aptamer
human study of milvexian，an oral，direct，small molecule inhibiting coagulation factor Ⅺa[J]. Sci Rep，2017，7（1）：
factor Ⅺ a inhibitor[J]. Clin Transl Sci，2022，15（2）： 2102.
330-342. [27] WOODRUFF R S，IVANOV I，VERHAMME I M，et al.
[17] RAO S V，KIRSCH B，BHATT D L，et al. A multicenter， Generation and characterization of aptamers targeting fac‐
phase 2，randomized，placebo-controlled，double-blind， tor Ⅺa[J]. Thromb Res，2017，156：134-141.
parallel-group，dose-finding trial of the oral factor Ⅺa in‐ （收稿日期：2024-02-04 修回日期：2024-08-22）
hibitor asundexian to prevent adverse cardiovascular out‐ （编辑：胡晓霖）

· 2170 · China Pharmacy 2024 Vol. 35 No. 17 中国药房 2024年第35卷第17期